Purpose: The aim of this study was to test the efficacy of Neurokinin-1 Receptor (NK-1R) antagonist ÀFosaprepitantÀ in inducing regression of established corneal neovascularization (CNV). Methods: Twenty C57BL/6 mice underwent alkali burn. Seven days later, when corneal neovessels had developed, they received Fosaprepitant 10 mg/ml, administered topically six times a day in the right eye for 10 days. In parallel, a group of 20 causticated mice was treated with normal saline, as control. A second independent experiment was also performed (n = 10/group). Finally, ten healthy mice received the same topical treatment for 10 days to evaluate Fosaprepitant safety. Haemangiogenesis and lymphangiogenesis were measured by means of VESSELJ plugin (IMAGEJ). Secondary endpoints, such as leucocyte infiltration, corneal opacity and corneal fluorescein staining were also evaluated. Inflammatory cell composition was assessed by flow cytometry.Differences between groups were assessed using unpaired t-test, Mann-Whitney U-test or two-way ANOVA, as appropriate. Results: Topical Fosaprepitant administration induced a significant reduction of (i) CD31 + blood corneal neovessels (À27%, p = 0.0132), (ii) LYVE1 + lymphatic corneal neovessels (À31%, p = 0.0118) and (iii) CD45 + leucocyte infiltration (À36%; p = 0.0237). The second independent experiment confirmed these data. Moreover, Fosaprepitant-treated corneas showed a reduction in opacity, no impairment in corneal fluorescein staining and decreased infiltration of neutrophils (À72%, p < 0.05) and macrophages (À75%, p < 0.01). Finally, topical Fosaprepitant was not toxic to the ocular surface: no signs of conjunctivitis, opacity, perforations or corneal fluorescein staining were detected. Similarly, corneal TUJ1 + nerve density was not affected. Conclusions: Our data suggest that NK-1R antagonists, such as Fosaprepitant, could be a new, promising therapeutic tool to inhibit CNV after this has been established.
Introduction
Corneal neovascularization (CNV) is an area of significant medical need.
The second cause of blindness worldwide (Skobe & Dana 2009 ), therapeutic options are currently limited. A number of compounds, including antiVEGFs, have been proven effective in patients with recent onset of CNV (Petsoglou et al. 2013) , whereas their efficacy in inducing regression of formed vessels has been limited to vessel calibre reduction (Dastjerdi et al. 2009; Cheng et al. 2012; Ferrari et al. 2013a,b,c) .
From a clinical point of view, treatments addressing vessels which are already invading the cornea -as opposed to preventing vessel growth into the cornea-would be highly beneficial. Indeed, patients frequently seek medical advice when neovessels have already developed. The aim of this study was to test the efficacy of NK-1R antagonist Fosaprepitant in inducing regression of haemangiogenesis and lymphangiogenesis in the cornea.
A wide range of corneal diseases, including trauma, infections and loss of limbal epithelial stem cells, are frequently associated with CNV (Chang et al. 2001) , which is directly associated with: (i) loss of visual acuity (Bachmann et al. 2013 ) and (ii) loss of the immune privilege of the cornea (Ellenberg et al. 2010) . Moreover, the extent of pre-existing CNV is directly related to the risk of corneal graft rejection (Bachmann et al. 2010) .
Medical treatments of CNV are limited. Topical steroids are widely used based on their inhibition of inflammatory cell migration and inflammatory cytokine secretion (Folkman 1995; Stevenson et al. 2012) . Steroids are known to be most effective if used for a long period of time, which leads to vision-threatening side-effects, including cataract induction, glaucoma and impaired wound healing (Shakiba et al. 2009; Fel et al. 2012 ).
Para-surgical or surgical treatments, such as photodynamic therapy, fine needle diathermy, laser-induced photocoagulation and conjunctival, limbal or amniotic membrane transplantation have been used to treat established CNV with variable success rates (Alio et al. 2005; Gerten 2008; Ang et al. 2010; Al-Torbak 2012; Trikha et al. 2014) .
Anti-VEGF drugs (i.e. Bevacizumab, Renabizumab), have been tested to treat pre-existing CNV in clinical trials Ferrari et al. 2013a,b,c) . Their topical administration is effective in reducing blood vessel calibre, but did not result in significant reduction in the corneal area invaded by neovessels (i.e. invasion area). Finally, occasional sideeffects (e.g. epithelial defects, corneal stromal thinning, neurotoxicity) have been reported when they were used to treat recent CNV (Bock et al. 2008; Kim et al. 2008; Koenig et al. 2009; Chang et al. 2012) . Indeed, anti-VEGFs are highly effective on neovessels before they are covered by pericytes, which is not the case in stable CNV (Bergers et al. 2003; Bergers & Hanahan 2008) .
Corneal neovascularization (CNV) is commonly associated with inflammation. Nerve-derived peptides play a key role in corneal inflammation and CNV (Ziche et al. 1990 (Ziche et al. , 1994 Bignami et al. 2014 ). This is not surprising, since the cornea receives the densest sensory innervation of the entire body. Specifically, Substance P (SP) is a neuropeptide of 11 amino acids, member of the tachykinin family, which is secreted from sensory nerve endings, including those in the cornea (Jones & Marfurt 1998; Muller et al. 2003) , and from various immune cells during inflammation (O'Connor et al. 2004) . Substance P exerts its actions through binding with the high-affinity neurokinin-1 receptor (NK-1R). This receptor is expressed on nerves, immune cells and epithelial cells (Krause et al. 1992) . The activation of NK-1R promotes lymphocyte proliferation, and induces the release of inflammatory mediators such as interleukins and growth factors needed to initiate and maintain CNV (O'Connor et al. 2004 ).
We previously proposed that NK-1R antagonists may have therapeutic applications in ocular disorders associated with neovascularization (Bignami et al. 2015) . We have recently confirmed that local administration of a high-affinity, competitive, NK-1R antagonist (i.e. Lanepitant) is effective in preventing the development of CNV (Bignami et al. 2014 ).
Here, we tested whether a selective NK-1R antagonist induces inhibition of pre-existing CNV (after 7 days of CNV, when pericytes are already present) (Ozerdem et al. 2005) , by blocking SP after vessels had invaded at least 50% of the corneal surface.
To this end, we used the NK-1R antagonist Fosaprepitant (also known as MK-0517 or L-758,298), a water soluble, clinically approved medication for prevention of nausea and vomiting (Langford & Chrisp 2010) .
Fosaprepitant is a prodrug, readily converted in vivo to active Aprepitant by ubiquitous phosphatases (Saito et al. 2013) , which are expressed in the cornea by epithelial cells, endothelial cells and keratocytes (Lessell & Kuwabara 1964; Cejkova & Bolkova 1977; Bolkova & Cejkova 1983 ).
Materials and Methods

Corneal alkali burn model
Female, 6-to 8-week-old, C57BL/6 mice (Charles-River, Calco, LC, Italy) were used for all experiments (total: 80 mice), as previously described (Bignami et al. 2014 A single investigator induced CNV in the right cornea of 60 mice, as previously described (Joussen et al. 2001) . Briefly, after general anaesthesia, corneal alkali burn was induced by application of 2 ll of 0.15 mM NaOH to the central cornea, and rinsed extensively with 20 ml of normal saline. The corneal epithelium was subsequently scraped off with a corneal knife in a rotary motion parallel to the limbus. To prevent infection, eyes were treated with antibiotic ointment, 1 time/day for the first 3 days.
After 7 days, corneas were examined and photographs were taken under the slit-lamp microscope SL 990 (C.S.O., Florence, Italy). Corneal neovascularization was clinically measured dividing the cornea in quadrants and giving a score, from 0 (no vessels) to 4 (vessels in four quadrants).
Out of 60 eyes, 20 were excluded from the study: five underwent perforation, two developed cataract and 13 showed neovascularization in just 1 quadrant. The remaining eyes were homogeneously divided into two groups (n = 20, each) on the basis of clinical scoring system for CNV.
The second independent experiment was conducted using 30 mice and 10 eyes per group (10 eyes were excluded).
Fosaprepitant treatment
The selected two groups received Fosaprepitant 10 mg/ml (IVEMEND, Merck Sharp & Dohme Ltd., Hoddesdon, UK) dissolved in a total volume of 10-ll phosphate-buffered saline (PBS, Sigma-Aldrich, St. Louis, MO, USA) or 10 ll of vehicle as control, topically six times a day in the right eye for 10 days. The treatments started 7 days after corneal injury ( Fig. 1) , when CNV was established, covering at least 50% of the corneal surface (Fig. S1 ).
We decided to administer topically 10 times the intravenous concentration (1 mg/ml) used in the treatment of chemotherapy-induced nausea and vomiting (Navari 2007 (Navari , 2008 , because in a preliminary experiment Fosaprepitant 1 mg/ml resulted ineffective in reducing both CNV and inflammation (Fig. S2) .
Fosaprepitant toxicity was evaluated in other two groups of 10 healthy animals (total: 20 mice) receiving in the right eye 10 ll of 10 mg/ml topical Fosaprepitant or PBS, six times a day for 10 days.
Clinical endpoints
At the end of each treatment, clinical examination was performed under the slit-lamp microscope to check gross pathologic changes and for drug toxicity, in a blinded fashion. A scoring system (from 0 to 4; 0 = completely clear, 4 = completely opaque) was used to evaluate corneal opacity, as previously described (Yoeruek et al. 2008) .
In vivo corneal fluorescein staining was used to evaluate defects on corneal epithelium after Fosaprepitant treatment, in both healthy and alkali burn eye. Eyes were photographed under a blue light (with o without a yellow filter) of the slit-lamp microscope SL 990. The percentage of green fluorescent area on the total corneal area was evaluated analysing images by IMAGEJ 1.44p software (National Institutes of Health, Bethesda, MD, USA).
The in vivo CNV invasion area was measured analysing the slit-lamp pictures by IMAGEJ, at 7 and 17 days (pre-and post-treatment time points respectively).
Corneal neovascularization and leucocyte infiltration analysis
At the end of any treatments, corneas were dissected, fixed and immunostained as previously described (Ferrari et al. 2013a,b,c) , for the following markers: rat anti-CD31 (blood marker; BioLegend, San Diego, CA, USA), goat anti-LYVE1 (lymphatic marker; AbCam, Cambridge, UK) and rabbit anti-CD45 (leucocyte marker; R&D System, Minneapolis, MN, USA).
Corneas were counterstained with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA), flat-mounted and photographed by epifluorescence microscope (Leica CTR5500; Leica Microsystems, Wetzlar, Germany). A set of six adjacent, overlapping images were acquired and remapped into a montage, obtaining a 2D reconstruction of the whole cornea. These digital pictures were analysed using a recently developed plugin for IMAGEJ, named VESSELJ (Rabiolo et al. 2015) , to quantify corneal blood-and lymph-angiogenesis in a semiautomatic fashion. CD45 + cell infiltration was quantified by counting the double positive (DAPI + CD45 + ) cells per field; six peripheral fields (940, 10 lm z-stack) per cornea were taken with a confocal microscope (Leica TCS SP5).
Corneal nerve analysis
Topically Fosaprepitant-treated healthy corneas were processed and immunostained for the nerve marker TUJ1 (rabbit anti-b3 tubulin polyclonal antibody; Chemicon, Temecula, CA, USA), as previously described (Ferrari et al. 2013a,b,c) , to evaluate the potential neurotoxicity of the drug.
Peripheral sub-basal nerve plexus was quantified in both Fosaprepitantand vehicle-treated groups by IMAGEJ, analysing six peripheral fields (940, 5 lm z-stack) per cornea, taken with the confocal microscope.
Flow cytometry analysis
At day 7 (before starting treatments) and 17 (after Fosaprepitant or vehicle treatments), 12 corneas/group were excised and pooled (3 corneas/pool). After removing the epithelium from the cornea with 20 mM EDTA, the stromal pool was made into single cell suspensions by collagenase IV (2 mg/ml, Sigma-Aldrich) and DNase I (0.5 mg/ ml, Roche) treatment in Hank's balanced salt solution (HBSS) with Ca 2+ /Mg 2+ medium. After shaking 60 min at 37°C, cell suspensions were 70 lm filtered and washed with cold PBS containing 0.5% BSA/2 mM EDTA. All cell suspensions were incubated with rat anti-Fcc III/II receptor blocking antibody (1:50; BD Biosciences) for 20 min on ice. Afterwards, they were stained for 30 min at 4°C with the following primary antibodies, previously titrated: rat anti-CD45-PB (1:200 dilution, 103126; Biolegend), rat antiCD11b-APC-eFluor780 (1:800dilution, 47-0112-82; eBiosciences), rat-anti- Fig. 1 . In vivo evaluation of corneal blood vessels after topical Fosaprepitant treatment. Representative slit-lamp pictures of alkali burn eyes before (day 7) and after (day 17) topical Fosaprepitant treatment (10 mg/ml, 6 times/day for 10 days), compared to healthy eyes before the burn (day 0). The treatments started 7 days after corneal damage, when CNV was established. Fosaprepitant-treated eyes showed less haemangiogenesis in vivo, in particular a reduced vascular density and calibre, as shown in the 29-magnified inserts.
Ly6G/Ly6C(GR1)-PE/Cy7 (1:200 dilution, 108415; Biolegend) and rat anti-F4/80-FITC (1:100 dilution, 123107; Biolegend). At the end, the cells were washed and re-suspended in 7-aminoactinomycin D (7-AAD; 1:100, 420403, Biolegend)-containing buffer.
Samples were acquired with Gallios flow cytometer (Beckman Coulter). To check instrument performance, to ensure robustness and reproducibility of the data between days 7 and 17, calibrator beads (8-peaks rainbow Beads, Spherotech) were used.
Gating strategy was based on the exclusion of dead cells (7AAD + ) from the analysis. After gating for doublet exclusion, myeloid cell population was characterized as CD45 + CD11b + . These myeloid cells include neutrophils, defined as GR1 high F4/80 -, and macrophages, defined as GR1 dim F4/80 + . All data were analysed using the FCS EXPRESS 4 software (DeNovo Software, Glendale, CA, USA).
Statistics
The clinical evaluations were analysed with unpaired Mann-Whitney U-test, whereas the flow cytometry and fluorescein analysis with two-way ANOVA following Tukey's multiple comparisons test. All other results were analysed with unpaired t-tests. Finally, v 2 test (without Yates correction) was performed to evaluate the incidence of central corneal avascularity.
Significance was defined as a p value <0.05. Results are presented as mean AE standard deviation (SD). All statistics were performed using GRAPH-PAD PRISM software 6.0 (GraphPad Software, Inc., San Diego, CA, USA).
Results
Topical Fosaprepitant reduces stable corneal neovascularization
After 7 days of established CNV (Fig. 1) , animals were divided into two groups (n = 20, each), homogeneously randomized in terms of CNV measured in quadrants (2.68 AE 0.51, Fosaprepitant versus 2.76 AE 0.42, vehicle; p = 0.6645) and in terms of opacity (3.37 AE 1.01, Fosaprepitant versus 3.53 AE 0.70, vehicle; p = 0.8485). During treatment, one eye per group underwent perforation (day 11, Fosaprepitant; day 9, vehicle), and excluded from analysis. The same selection criteria were applied for the second independent experiment (n = 10/ group). Topical Fosaprepitant administration for 10 days induced a significant reduction of (i) blood corneal neovessels (0.072 AE 0.032, Fosaprepitant versus 0.099 AE 0.031, vehicle; À27%, p = 0.0132), and (ii) lymphatic corneal neovessels (0.022 AE 0.011, Fosaprepitant versus 0.032 AE 0.011, vehicle; À31%, p = 0.0118), (Fig. 2) . In addition, in the second experiment, the data were confirmed, showing a 33% reduction of haemangiogenesis (p = 0.0294) and a 51% decrease of lymphangiogenesis in the Fosaprepitant-treated eyes (p = 0.0452).
Of note, a reduction in blood vessel calibre was noted in the Fosaprepitanttreated corneas, both in vivo (Fig. 1 , magnified images) and ex-vivo (Fig. 2 , magnified inserts).
Topical Fosaprepitant improves corneal transparency and does not affect epithelial wound healing
Fosaprepitant treatment was effective in reducing corneal opacity in comparison to vehicle, although not significantly (3.26 AE 1.24, Fosaprepitant versus 3.84 AE 0.50, vehicle; À15%; p = 0.0829), as in the second independent experiment. Moreover, the central area of the cornea (i.e. the nearest to visual axis and most important for visual acuity) was free of blood vessels (Fig. S3 ) in 47% of Fosaprepitanttreated eyes (9 corneas on a total of 19), compared to the 21% (4 corneas out of 19) in the vehicle group (p = 0.0873). The repeated experiment confirmed these data (80% in the Fosaprepitant group versus 40% in the vehicle group; p = 0.0679).
Topical application of Fosaprepitant did not impair the epithelial wound closure rate in both experiments (Fig. 3) . On the contrary, in only one experiment, fluorescein staining was slightly reducedalthough not significantly -after 10 days of treatment (Fosaprepitant: from 58.10% AE 14.69 to 46.40% AE 13.45, À20%, p = 0.1397; vehicle: from 48.33% AE 14.66 to 49.11% AE 13.18, +2%, p = 0.9239), (Fig. 3B) . high F4/80 -neutrophils (À72%, from 16.52 AE 4.24 to 4.67 AE 1.20%; p < 0.05), as shown in Fig. 4B . Topical Fosaprepitant is not toxic to the ocular surface Topical Fosaprepitant (10 mg/ml, 6 times/day per 10 days) treatment was not toxic to the ocular surface of healthy eyes as assessed with slit-lamp exam: no signs of hyperaemia/conjunctivitis or perforations were detected. Moreover, treated corneas remained transparent (Fig. 5A ). In addition, Fosaprepitant was not toxic to the corneal epithelium, as confirmed by negative fluorescein staining (Fig. 5A) .
Finally, the NK-1R antagonist did not show a toxic effect on corneal nerves, as confirmed by representative histological pictures of the peripheral sub-basal nerve plexus immunostained with anti-TUJ1 antibody (Fig. 5B) and by TUJ1 + nerve quantification (Fig. 5C ), compared to vehicle-treated healthy corneas (n = 5, p = 0.7581).
Discussion
Substance P promotes CNV by binding to its receptor NK-1R. We recently demonstrated that topical administration of the NK-1R antagonist Lanepitant prevents corneal haem-and lymphangiogenesis (Bignami et al. 2014) . Here, we show that Fosaprepitant 10 mg/ml, a high-affinity NK-1R antagonist, significantly reduces established CNV, in two independent experiments. Interestingly, the central area of the cornea (i.e. the nearest to visual axis) tended to be free of blood vessels more frequently in Fosaprepitant-treated eyes, although not significantly. We anticipate that our finding may have relevant clinical implications, since CNV is the second cause of blindness worldwide (Skobe & Dana 2009 ). In addition, CNV is a known risk factor for corneal graft rejection (Dietrich et al. 2010) . Interestingly, Fosaprepitant is freely water soluble (Hale et al. 2000) , and it is rapidly converted to Aprepitant in vivo (Navari 2007) , which makes its eye drop formulation convenient.
In addition to CNV inhibition, Fosaprepitant treatment also reduced corneal inflammation, as confirmed by our immunostaining and flow cytometry data. It is known that leucocytes, and specifically macrophages, express the NK1 receptor, and that its activation leads to increased macrophage activity and chemotaxis (Kavelaars et al. 1994) , and release of pro-angiogenic factors, such as SP and VEGF (Ziche et al. 1990; Li et al. 2012; Lu et al. 2012) . Since leucocytes have proven instrumental for the development of both corneal haemangiogenesis ( Van der Veen et al. 1994; Li et al. 2013 ) and lymphangiogenesis (Cursiefen et al. 2004; Maruyama et al. 2012) , their decrease following treatment could have a role in CNV reduction. Hence, it could be speculated that Fosaprepitant may modulate inflammatory cell recruitment, and activation state, which could finally result in the reduction of vessel density.
In addition, Fosaprepitant also ameliorated other inflammation-related clinical outcomes such as corneal transparency and epithelial defect size. This is in line with our previous findings with different NK-1R antagonists (Bignami et al. 2014) .
Finally, topical Fosaprepitant was not toxic to the ocular surface: no signs of conjunctivitis, perforations, corneal opacity, or epithelial defects were detected when it was tested on healthy eyes. Also the sub-basal nerve plexus was not affected by the treatment. This is in accordance with our previous observations with other NK-1R antagonists (Bignami et al. 2014) . Although toxicity of topical Fosaprepitant has not been tested in humans yet, its systemic administration did not reveal serious adverse events or toxicity (Lasseter et al. 2007 ).
In conclusion, Fosaprepitant: (i) is the only water-soluble NK-1R antagonist currently approved for clinical use, (ii) does not show evident ocular surface toxicity and (iii) it effectively reduces growth of pre-existing CNV in animal models. Hence, we suggest that Fosaprepitant is an ideal candidate for CNV clinical trials in humans. 
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